Drug intelligence / Profile preview

escitalopram + omega-3 polyunsaturated fatty acids

Development stage
Unknown
Lead developer
Lundbeck
Modality
Small Molecules
Administration
Oral
01

Overview

This is a combination therapy consisting of escitalopram, a selective serotonin reuptake inhibitor (SSRI) antidepressant, and omega-3 polyunsaturated fatty acids (PUFAs), commonly found in fish oil supplements. Escitalopram acts by inhibiting the reuptake of serotonin in the brain, thereby increasing its availability and improving mood. Omega-3 PUFAs—primarily eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA)—are thought to exert neuroprotective and anti-inflammatory effects that may enhance antidepressant efficacy. Clinical studies suggest that combining these agents can result in greater improvement of depressive symptoms compared to either agent alone[1][3][4]. This combination is being explored primarily for the treatment of depression.

Other names
escitalopram + omega-3 PUFAsescitalopram + fish oilescitalopram + omega-3 fatty acids
02

Targets

SERT (Sodium-dependent serotonin transporter)

Beyond the preview

Go deeper on escitalopram + omega-3 polyunsaturated fatty acids.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on escitalopram + omega-3 polyunsaturated fatty acids.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call